Loading
A phase 1/2 trial of Repotrectinib in advanced solid tumours, run by Turning Point Therapeutics, Inc., now recruiting.
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements is a phase 1/2 interventional study registered as NCT03093116 by Turning Point Therapeutics, Inc., with 500 participants planned, started 2017-03-07 and due to reach its primary completion in 2028-02-29. Interventions recorded: Oral repotrectinib (TPX-0005).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Repotrectinib, ROS1-positive non-small-cell lung cancer, Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.
Shares Repotrectinib, Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/